FDA Inspection
Actavis Elizabeth LLC, A Company of TevaActavis Elizabeth LLC, A Company of Teva – FDA Inspection, Feb 15, 2017
Record Details
This FDA Inspection record concerns Actavis Elizabeth LLC, A Company of Teva, with an inspection on February 15, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
- People
- Guerlain Ulysse (FDA Associated Person)
- Sachinkumar V. Patel (Issuing Officer)
- Yvesna C. Blaise (Issuing Officer)
View Company Profile
ID · 9b6667bd-1d96-462e-a29c-cd32805f69ee
Inspection Facts
No Action Indicated (NAI)
No objectionable conditions or practices were found during the inspection.
- Inspection number
- 1003801
- FDA center
- Human Drugs
- Project area
- Generic Drug Evaluation
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 211.165(a)Testing and release for distribution
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Actavis Elizabeth LLC, A Company of Teva
14| Date | Classification | Office | Project area |
|---|---|---|---|
| July 24, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 5, 2018 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 19, 2017 | Not classified | New Jersey District Office | |
| December 5, 2016 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 27, 2015 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Actavis Elizabeth LLC, A Company of Teva
- FDA Inspection 1215838 - 2023-07-24
- FDA Inspection 1041770 - 2018-02-05
- FDA Inspection 1017122 - 2017-05-19
- FDA Inspection 994679 - 2016-12-05
- FDA Inspection 939866 - 2015-08-27
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.